McKinsey River Capital Management Life Sciences
One of Europe's Largest and Most Experienced Life Sciences Investors
With a team of experienced investment professionals comprising medical, scientific, and industry experts, we look for the smartest inventors with ideas that have the potential to improve patients’ lives. We contribute not only capital, but also strategic, clinical, operational, financial, and commercial guidance and support, to provide the added value that inventors seek.
MRC Life Sciences has a 30-year history, raising more than 3 billion euros and investing in over 150 private companies.
MRC Life Sciences, formerly LSP, is one of Europe’s largest and most experienced Life Sciences investors. We target innovative companies focusing on the development of therapeutics, medical devices, diagnostics, and healthtech globally. With a track record going back 30 years, MRC Life Sciences has raised around 3.5 billion euros across 12 private funds and 3 investment strategies. With a dedicated team of highly experienced investment professionals, coming from backgrounds in medicine and science, MRC Life Sciences aims to back the smartest inventors who have ideas that could truly make a difference for patients.
Investing to improve patients’ lives
Nowadays, too many people suffer from diseases that are not diagnosed accurately, not treated properly, not cured satisfactorily, or not cured at all. MRC Life Sciences is passionate about transforming cutting-edge scientific innovation into impactful healthcare solutions to address these challenges. We believe that the only way to do this sustainably is by identifying the most innovative solutions to the greatest unmet clinical needs, and to consistently strive for superior returns for our investors. We are proud to see the results of our work improving the quality of life for patients around the world.
Our Investment Strategies
Life Sciences Funds (LSP 1-7)
Biotech funds focused on drug development at all stages.
Health Economic Funds
Later-stage MedTech, Digital Health and Diagnostics focus to enhance care quality and reduce healthcare costs.
Dementia Fund
Drug development and medical technology for neurodegenerative diseases.
Long-term Growth Drivers for Life Sciences
01
Demographic Trends
Growing and aging population with increasing lifestyle-related diseases.
02
Unmet Medical Need
High impact as millions of people suffer from conditions with limited or no effective treatments, including cancer, neurodegenerative disorders (e.g., Alzheimer’s), rare diseases, and antibiotic-resistant infections.
03
Record Innovation Level
The rapid pace of medical discoveries, particularly in Europe and the US, highlights Europe’s strong science (three of the first four COVID vaccines were developed there) and its lower capital availability compared to the US, creating favorable investment opportunities.
04
Market Momentum
M&A activity within Life Sciences is high and expected to increase further, driven by the fact that 40% of Big Pharma revenues are at risk through 2030 as products come off patent.
Spotlight On Life Sciences
Healthcare
The Promise of ‘Guided-Missile’ Cancer Drugs
The Making of a $1bn Biotech
Our Funds
LSP 7
Launch
2021
Size
1B EUR
Strategy
Life Sciences
LSP 6
Launch
2018
Size
550M EUR
Strategy
Life Sciences
LSP HEF 2
Launch
2018
Size
280M EUR
Strategy
Health Economics
LSP 5
Launch
2014
Size
250M EUR
Strategy
Life Sciences
LSP Dementia Fund
Launch
2020
Size
273M EUR
Strategy
Dementia
Do You Want to Submit an Investment Opportunity?
We want to hear from entrepreneurs with great ideas. Email us using the button below to submit your investment opportunity.
Featured Companies from Our Portfolio
Innovations that improve the quality of life for people with rare diseases.
Amolyt Pharma is dedicated to creating treatment options that significantly improve the quality of life for individuals with rare endocrine disorders.
Founded by a team with extensive experience in both peptide drug development and the endocrine therapeutic area, Amolyt combines deep scientific expertise with an unwavering focus on patient needs. The company’s lead program is a groundbreaking therapy currently in late-stage clinical trials for hypoparathyroidism, a severe condition characterized by calcium imbalance. Existing treatments often carry long-term risks, such as kidney damage or adverse effects on bone health, posing additional challenges for a population already predisposed to osteoporosis due to age and gender factors.
Amolyt’s innovative approach addresses these issues by restoring calcium balance in a more physiological and effective manner, potentially offering a transformative solution without the complications associated with traditional therapies. By tackling these critical unmet needs, Amolyt Pharma is aimed at redefining care for hypoparathyroidism and setting a new standard in endocrine disorder treatment.
Key Facts
Sector Healthcare
Country France
Fund LSP 6
Entry 2019
Exit 2024
Driving progress in stroke therapy
Neuravi, founded in 2009, has developed an innovative stroke treatment that significantly enhances patient outcomes by preserving abilities and saving lives.
The company’s flagship device, the EmboTrap, is specifically designed to efficiently remove clots from the brain — the primary cause of strokes — thereby facilitating recovery. In 2017 and just two years after receiving its initial investment by EQT Life Sciences, Neuravi was acquired by Johnson & Johnson. Today, EmboTrap devices are widely used to treat patients in both Europe and the United States.
Key Facts
Sector Healthcare
Country Ireland
Fund LSP 5, LSP HEF 1
Entry 2015
Responsible advisors René R. Kuijten
New Amsterdam Pharma
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well-tolerated.
NewAmsterdam Pharma seeks to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor in patients at risk of cardiovascular disease, for whom existing therapies are not sufficiently effective or well-tolerated. Obicetrapib is also being investigated as a potential treatment for Alzheimer’s disease.
Key Facts
Sector Healthcare
Country Netherlands
Fund LSP Dementia
Entry 2024
Website newamsterdampharma.com
A medtech company that has reimagined how sleep diagnosis can be performed
A medtech company that has reimagined how sleep diagnosis can be performed
Onera Health is a Medtech/Digital Health company that has reimagined how sleep diagnosis can be performed. Current standard of care (a test called polysomnography or PSG), is expensive (it requires people, buildings and equipment), is inconvenient (it requires the patient to be assessed in a sleep clinic), and it has excessive waiting times that can be months or even years depending on where you live.
Based in the Netherlands, Onera has created a self applied, easy to use and wireless solution that generates the same quality and reliability of information as the standard of care, but from the comfort of the patient’s own home. Faster access to sleep assessment allows patients to gain a diagnosis, and receive treatment much more quickly and in a more cost effective way.
News
Do You Want to Know More?
We are eager to explore how we can achieve great things together.
Exclusive News and Insights
Press the button below to sign up for our EQT Foundation newsletters.
